Complete Resolution of Locally Advanced Prostate Cancer After Molecular Endoradiotherapy With 177 Lu-PSMA

A 76-year-old man with castration-resistant prostate cancer underwent 68 Ga-prostate-specific membrane antigen (PSMA) PET/CT for restaging. A large PSMA-avid tumor with invasion to adjacent organs was noted causing gross hematuria and symptomatic anemia. Two cycles of 177 Lu-PSMA were administered,...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2024-06, Vol.49 (6), p.e276-e277
Main Authors: Beheshti, Mohsen, Vali, Reza, Zarehparvar Moghadam, Soroush, Amini, HamidReza, Hakiminejad, Masoumeh, Divband, GhasemAli
Format: Article
Language:English
Subjects:
Aged
Humans
Lutetium
Male
Positron Emission Tomography Computed Tomography
Prostate-Specific Antigen
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - pathology
Radioisotopes - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 76-year-old man with castration-resistant prostate cancer underwent 68 Ga-prostate-specific membrane antigen (PSMA) PET/CT for restaging. A large PSMA-avid tumor with invasion to adjacent organs was noted causing gross hematuria and symptomatic anemia. Two cycles of 177 Lu-PSMA were administered, and the patient showed significant reduction of hematuria as well as declining in PSA levels. 177 Lu-PSMA therapy can be a good treatment option in patients with locally invasive tumors.
ISSN:1536-0229
DOI:10.1097/RLU.0000000000005163